Nivestim(TM) in Treatment of Malignant Diseases

• Number of adverse events [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]
  Any hospitalization regardless of the correlation to febrile neutropenia and/or infection and adverse events will be reported and documented on teh AE form in teh respective CRF of teh participants.
• Changes to efficacy parameters from baseline to 6 months [ Time Frame: 6 months ] [ Designated as safety issue: Yes ]

  Description of the efficacy of treatment with Nivestim(TM) which includes the following parameters:

  • Duration of neutropenia
  • Incidence of febrile neutropenia
  • Frequency of infection
  • Delay in chemotherapy cycles due to neutropenia
  • Reduction in chemotherapy doses due to neutropenia
  • Assessment of patient

This is a non-interventional, descriptive, national, multi-site, longitudinal and prospective observational study with in-patients adults or minors undergoing cytotoxic chemotherapy, being treated prophylactically with NivestimTM in order to reduce the duration of neutropenia and to reduce the incidence of chemotherapy-induced Febrile neutropenia (FN).

To observe the tolerability, safety and efficacy of preventative treatment using NivestimTM in patients receiving cytotoxic chemotherapy for cancer.

To investigate the description of the characteristics of patients being treated with NivestimTM, the treatment modalities using NivestimTM in the daily Routine, to investigate the description of the characteristics of the participating Physicians and to determine the general prescription practices of these physicians with regard to G-CSF.

Children and adult patients with a solid tumor or a malignant haematological tumor due to under go prophylatic treatment using Nivestim/

• Solid Tumor
• Malignant Hematological Tumor
• Primary or Secondary Prophylactic Treatment

Inclusion Criteria:

• No age limit
• Declaration of informed consent signed by patient or legal guardian
• Patients with a solid tumour or with a malignant haematological tumour
• Patients for whom cytotoxic chemotherapy is planned, irrespective of cycle
• Patients who are due to undergo, or who should undergo, (primary or secondary) prophylactic treatment using NivestimTM, either to shorten the duration of a neutropenia or to prevent the occurrence of chemotherapy induced FN.

Exclusion Criteria:

• Patients with chronic myeloid leukaemia (CML) or with myelodysplastic
• Syndrome (MDS)
• Patients who are hypersensitive to the active substance or to one of the
• Excipients of NivestimTM
• Patients not undergoing chemotherapy
• Patients being treated curatively with G-CSF